Stem Cell Conditioned Media: Companies, Startups & Research

FACTS list 198 companies and 25 startups, including Accelerated Biosciences Corporation, Tissuecare Biotechnology and Acorn Biolabs Inc. Their work includes trophoblast stem-cell secretomes and exosomes, conditioned-medium research, and a clinical trial evaluating autologous hair-follicle secretome for facial rejuvenation. The list identifies participants, but does not establish which company has the strongest product or evidence.

Universitas Indonesia has 36 recent documents, Airlangga University has 34, and Sun Yat Sen University has 27. Their work includes hair regeneration and keloids, umbilical-cord MSC secretome for bone repair, and extracellular-vesicle research on dental-pulp repair and stromal-cell senescence. These activity figures indicate recent research output, not a ranking of scientific quality.

FACTS associate $36.2 million in grants across 21 grants since 2020, plus $757.4 million across 14 funding rounds. These figures describe funding linked to organizations in the field and may include broader organizational activity, rather than financing dedicated to conditioned media. Review individual records before using the totals to assess investment in a specific product or program.

Direct biologics, llc has 8 listed patents, followed by Combangio Inc. with 5 and Taipei Medical University with 4. The counts identify leading holders in the supplied patent data; they do not show patent scope, enforceability or commercial value. Patent claims should be reviewed individually to determine whether they cover a particular secretome, production method or use.

FACTS report 103 patents in the 24-month window and a patent-growth figure of -54.9%. By contrast, publications reached 1,201 last year, with growth of 10.5%. This points to stronger recent publication activity than patent activity in the available data, but the figures alone do not explain the shift or indicate the quality of individual inventions.

The field has 10,827 publication records, 665 patent records and 86 clinical-trial records in FACTS. This shows substantial research activity alongside some clinical investigation, but those totals do not establish that a specific conditioned-medium product is approved or clinically effective. Product maturity depends on evidence for its source cells, manufacturing consistency, safety and intended use.

Recent examples include IIMS-UT Health San Antonio’s October 2026 report on automated iPSC expansion linked to extracellular-vesicle production, and an August 2026 lyophilized conditioned-medium formulation studied by Tsinghua University and Jiaxing University for wound repair. October 2026 also brought ABio materials’ Celexo AAPE launch, combining conditioned media with plant-derived exosomes and olive-derived PDRN.

FACTS identify 5 approaches: unfractionated secretome, extracellular-vesicle enrichment, soluble-factor fractions, cell priming and three-dimensional production. Whole secretome preserves a broad mixture but is harder to standardize; vesicle enrichment narrows the focus but adds isolation challenges. Priming and three-dimensional production seek to shape secretion, while each introduces additional process variables. The best fit depends on the intended product and evidence needs.

The United States has 3,054 records and China has 2,585, the largest country totals in FACTS. Italy follows with 872, and South Korea with 838. These figures describe recorded activity, not a direct comparison of research quality, commercial readiness or clinical outcomes. The field also has substantial activity in countries including Iran, Japan and the United Kingdom.

FACTS identify wound healing, musculoskeletal repair, neurological recovery, hair restoration, ocular repair, and skin repair and aesthetics as application areas. Wound healing has 525 records, musculoskeletal repair 298 and neurological recovery 222. Recent research also examines dental-pulp repair, liver protection and other uses. These counts reflect activity, not proof that a treatment works in patients.